Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Entries Could Boost Generic Drug Image In Japan - JGA President

This article was originally published in PharmAsia News

Executive Summary

Japan Generics Association President Hiroyuki Sawai said the recent generics entries of Pfizer and Daiichi Sankyo could help boost the generic drug image in Japan. Sawai said the wall between innovative and generic drug makers is disappearing and the major drug makers will establish new quality and trust for the industry. Many Japanese generics manufacturers are small to mid-sized, and generic drugs are considered in Japan to be lower in quality than brand products. JGA has implemented a series of programs to emphasize the quality and safety of generic drugs. Sawai also said that compared to the EU and the U.S., Japan still lacks systemic support to stimulate generics use, and he expects the industry will grow further as the government implements promotional measures. (Click here for more - Japanese language

You may also be interested in...

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain

Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts